Online citations, reference lists, and bibliographies.
← Back to Search

Cerebral Amyloid Angiopathy And The Fibrinolytic System: Is Plasmin A Therapeutic Target?

Chloe A Mutimer, C. Keragala, H. Markus, D. Werring, G. Cloud, R. Medcalf
Published 2021 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Cerebral amyloid angiopathy is a devastating cause of intracerebral hemorrhage for which there is no specific secondary stroke prevention treatment. Here we review the current literature regarding cerebral amyloid angiopathy pathophysiology and treatment, as well as what is known of the fibrinolytic pathway and its interaction with amyloid. We postulate that tranexamic acid is a potential secondary stroke prevention treatment agent in sporadic cerebral amyloid angiopathy, although further research is required.
This paper references
10.1111/j.1532-5415.1981.tb01757.x
Cerebral Amyloid Angiopathy in the Elderly
M. Tomonaga (1981)
10.1038/NM0295-138
In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues
I. B. Kinston (1995)
10.1523/JNEUROSCI.20-11-03937.2000
The Plasmin System Is Induced by and Degrades Amyloid-β Aggregates
H. Tucker (2000)
10.1002/14651858.cd001245
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.
Y. Roos (2000)
Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy.
F. Gervais (2001)
10.1182/BLOOD.V97.12.3941
Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation.
T. Syrovets (2001)
10.1212/WNL.56.4.537
Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston Criteria
K. Knudsen (2001)
10.1016/S0967-5868(02)00317-X
Prevalence of cerebral vascular amyloid-β deposition and stroke in an aging Australian population: a postmortem study
F. Mastaglia (2003)
Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells.
Sonia S. Jung (2003)
10.1002/ana.10671
Matrix metalloproteinase–9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy
J. Lee (2003)
10.1038/nn1302
Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis
M. Herzig (2004)
10.1016/j.neulet.2004.07.011
Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice
H. Tucker (2004)
10.1515/REVNEURO.2004.15.5.353
Mouse Models of Alzheimer's Disease: Insight into Treatment
D. German (2004)
10.1148/RG.265055090
Cerebral amyloid angiopathy: CT and MR imaging findings.
C. Chao (2006)
10.1016/J.JTBI.2005.07.005
Mechanisms to explain the reverse perivascular transport of solutes out of the brain.
D. Schley (2006)
10.1073/pnas.0710823105
Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade
J. S. Jacobsen (2008)
10.1111/j.1365-2990.2007.00926.x
Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology
R. Carare (2008)
10.1186/1471-2377-9-3
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review
H. Keage (2009)
10.1007/s00401-009-0501-8
Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies
T. Revesz (2009)
10.1182/blood-2009-02-203448
A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.
A. Samson (2009)
10.1212/WNL.0b013e3181eee40f
Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy
A. Biffi (2010)
10.1212/WNL.0b013e3181f002c1
Prevalence of Superficial Siderosis in Patients with Cerebral Amyloid Angiopathy
H-L Zhang (2010)
10.1161/STROKEAHA.109.563932
Effects of Perindopril-Based Lowering of Blood Pressure on Intracerebral Hemorrhage Related to Amyloid Angiopathy: The PROGRESS Trial
H. Arima (2010)
10.1161/ATVBAHA.109.202044
Plasmin Triggers Chemotaxis of Monocyte-Derived Dendritic Cells Through an Akt2-Dependent Pathway and Promotes a T-Helper Type-1 Response
Xuehua Li (2010)
Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease
M Cortes-Canteli (2010)
10.1016/J.YMED.2011.09.015
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis
R. Panush (2011)
10.1002/14651858.CD001886.pub4
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
D. Henry (2011)
10.1093/brain/awr172
Acute ischaemic brain lesions in intracerebral haemorrhage: multicentre cross-sectional magnetic resonance imaging study.
S. Gregoire (2011)
10.2217/WHE.11.65
Long-Term Evaluation of Safety and Health-Related Quality of Life in Women with Heavy Menstrual Bleeding Treated with Oral Tranexamic Acid
K. Muse (2011)
10.1111/j.1365-2990.2010.01137.x
Review: Sporadic cerebral amyloid angiopathy
J. Attems (2011)
10.1016/S1474-4422(10)70325-2
Apolipoprotein E in Alzheimer's disease and other neurological disorders
P. Verghese (2011)
10.1182/blood-2011-11-389668
Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
D. Zamolodchikov (2012)
10.1155/2012/141806
So Many Plasminogen Receptors: Why?
E. Plow (2012)
10.1016/S0140-6736(12)61591-8
Thrombolysis in acute ischaemic stroke
D. Fatovich (2012)
10.2165/11209070-000000000-00000
Tranexamic Acid
P. L. McCormack (2012)
10.1111/acel.12045
Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid‐β from the mouse brain
C. Hawkes (2013)
10.1016/j.jocn.2012.11.029
Cerebral amyloid angiopathy causing cortical microinfarction
W. Vallat (2013)
10.1111/nan.12042
Review: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy
R. Carare (2013)
10.1038/ncomms6659
The role of protein clearance mechanisms in organismal ageing and age-related diseases.
D. Vilchez (2014)
10.1111/anae.12516
The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients
V. Sharma (2014)
10.1038/jcbfm.2014.99
Plasmin-Dependent Modulation of the Blood–Brain Barrier: A Major Consideration during tPA-Induced Thrombolysis?
B. Niego (2014)
White matter perivascular spaces : an MRI marker in pathology - proven cerebral amyloid angiopathy ?
A Charidimou (2014)
White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology
A Charidimou (2014)
10.1001/jama.2015.10082
Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.
A. Biffi (2015)
10.1016/j.neurobiolaging.2014.10.030
Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration
M. Cortés-Canteli (2015)
10.1007/s00401-016-1635-0
Reduced vascular amyloid burden at microhemorrhage sites in cerebral amyloid angiopathy
S. V. van Veluw (2016)
10.1212/WNL.0000000000002362
White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy
A. Charidimou (2016)
10.1016/j.bbadis.2015.08.024
Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy☆
A. Keable (2016)
10.1001/jamaneurol.2016.0292
Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden: A Meta-analysis.
G. Tsivgoulis (2016)
10.1002/ana.24558
Tranexamic acid–associated seizures: Causes and treatment
Irene Lecker (2016)
10.1093/brain/awv313
Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity.
K. Bales (2016)
10.1523/JNEUROSCI.2932-15.2017
Plasminogen Deficiency Delays the Onset and Protects from Demyelination and Paralysis in Autoimmune Neuroinflammatory Disease
M. Shaw (2017)
10.1111/jth.13849
Fibrinolysis: from blood to the brain
R. Medcalf (2017)
10.1136/jnnp-2016-314697
The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice
G. Banerjee (2017)
10.1172/JCI90609
CNS inflammation and neurodegeneration.
T. Chitnis (2017)
10.1038/s41590-018-0232-x
Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration
J. Ryu (2018)
10.1097/WCO.0000000000000510
The growing clinical spectrum of cerebral amyloid angiopathy
M. Wermer (2018)
10.1016/S0140-6736(18)31878-6
Intracerebral haemorrhage: current approaches to acute management
C. Cordonnier (2018)
10.1016/S0140-6736(18)31033-X
Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial
N. Sprigg (2018)
10.1080/14737175.2018.1480938
Cerebral amyloid angiopathy: diagnosis and potential therapies
S. Weber (2018)
10.1038/nrn.2018.13
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Mark A Petersen (2018)
10.1016/S1474-4422(18)30006-1
The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study
M. Rodrigues (2018)
TICH-2 Investigators. Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebocontrolled, phase 3 superiority trial
N Sprigg (2018)
10.1016/j.brainres.2019.04.014
Impaired dynamic cerebral autoregulation in patients with cerebral amyloid angiopathy
M. Reinhard (2019)
10.1016/j.jtcvs.2018.09.113
Tranexamic acid in coronary artery surgery: One‐year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial
P. Myles (2019)
10.1016/S0140-6736(19)32233-0
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial
The CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators (2019)
10.1111/jth.14603
Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis
D. Draxler (2019)
10.1177/1747493019855888
Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0
A. Charidimou (2019)
10.1161/STROKEAHA.118.023788
Blood-Brain Barrier Leakage and Microvascular Lesions in Cerebral Amyloid Angiopathy
W. Freeze (2019)
10.1016/S0140-6736(19)30840-2
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
Rustam MS PAG CLM JM WN GD J DE N DJ PM Colin Daniel Fran Al-Shahi Salman Dennis Sandercock Sudlow Wardlaw W (2019)
10.1073/pnas.1921327117
Cerebral amyloid angiopathy-linked β-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen
Steven A Cajamarca (2020)
10.1016/S0140-6736(20)30848-5
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial
Ian Haleema Adefemi Adegboyega Monica Amy Rizwana Ian Roberts Shakur-Still Afolabi Akere Arribas Brenner (2020)
10.3390/ijms22083869
Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy
Y. Inoue (2021)



Semantic Scholar Logo Some data provided by SemanticScholar